TrialsgrambetaRCTs are beautiful

CANTOS

2017

Canakinumab Anti-inflammatory Thrombosis Outcomes Study

In 10,061 patients with prior MI and elevated CRP, canakinumab reduced recurrent cardiovascular events compared with placebo.

Result

Efficacy: CV death, MI or strokeHR 0.85 (95% CI 0.74-0.98) · P = 0.021

Below 1 favours canakinumab, above 1 favours placebo.

Also reported: More fatal infections; no LDL change

Original publication
Subtopic
Anti-inflammatory
Design
Double-blind RCT
Relevance
Important: one of several pillars.
Source
Ridker PM, et al. N Engl J Med. 2017;377(12):1119-1131.doi 10.1056/NEJMoa1707914

Discussion & critique

Proved the inflammatory hypothesis of atherosclerosis with a lipid-neutral drug. Cost and infection risk preclude routine use; pointed the way to colchicine.

Discussed in podcasts